Drug--drug interactions in patients with cancer are common, and most drug--drug interactions can cause considerable adverse drug reactions (ADRs) ([@bib20]). In the general population, it has been reported that 20--30% of all ADRs are caused by drug--drug interactions ([@bib20]). Drug--drug interactions are estimated to be the cause of death in ∼4% of cancer patients ([@bib7]). Patients treated systemically for cancer are particularly at risk for drug--drug interactions. Typically, patients with cancer receive a high number of drugs concomitantly, including cytotoxic agents, hormonal agents, targeted agents, and supportive care agents among medication prescribed to treat comorbidities. An additional problem is that the mean age of cancer patients is increasing. Older patients generally have more comorbidities for which they also receive drug treatment ([@bib43]). The risk for drug--drug interactions in elderly cancer patients is further increased because of altered age- and comorbidity-related physiologic changes (e.g., altered drug absorption due to mucositis or altered excretion due to renal and hepatic impairment) ([@bib31]).

Here, a potential drug--drug interaction (PDDI) was defined as the occurrence of a potentially harmful combination of prescribed drugs in a given patient, rather than the occurrence of an actual adverse event for a patient.

In clinical practice, PDDIs can be distinguished as pharmaceutical, pharmacokinetic, and pharmacodynamic interactions ([@bib31]). Pharmaceutical PDDIs occur for instance when two chemically or physically incompatible compounds are combined (e.g., cisplatin and mesna; [@bib41]). Pharmacokinetic interactions refer to an influence on the absorption, distribution, metabolism, or elimination of the drug itself or a combination of drugs. A common pharmacokinetic interaction concerns drugs metabolised by the cytochrome P450 (CYP) enzymes. By inhibition or induction of CYP iso-enzymes, blood and tumour concentrations, antitumoural effects, and toxicities of specific anticancer therapies may be altered. Other pharmacokinetic interactions may result from, that is, inhibition of the ABCB1 efflux-transporter (or P-glycoprotein); by altering the activity of ABCB1, the bioavailability of anticancer drugs may be influenced. Pharmacodynamic drug interactions usually occur when two or more drugs have a similar mechanism of action. The effect can be synergistic, additive, or antagonistic. Pharmacodynamic drug interactions can be beneficial (e.g., enhanced pharmacologic effects with fluorouracil and leucovorin), but may also be potentially harmful (e.g., ototoxicity with furosemide and cisplatin; [@bib6]).

In general medicine, the prevalence of PDDIs and their determinants has been evaluated in several studies ([@bib8]; [@bib11]; [@bib12]). By contrast, data on the prevalence of PDDIs with anticancer drugs are scarce. Two studies, conducted in ambulatory cancer patients, found that 27--58% of all patients had at least one PDDI ([@bib29]; [@bib40]). Determinants for PDDIs were an increasing number of drugs, the use of OTC drugs, type of medication (drugs to treat comorbid conditions only), and the presence of brain tumours. However, these studies included only outpatients receiving intravenous anticancer treatment at a day-treatment facility ([@bib29]; [@bib40]). A retrospective database study, involving cancer patients on oral anticancer therapy, found that 5% of all patients had at least one potentially interacting drug combination ([@bib18]).

In the last decade, the availability and use of oral anticancer agents has increased dramatically. In comparison with parenteral treatment, the administration of oral agents is usually believed to be more convenient for the patient ([@bib3]). However, due to chronic use and the fact that most anticancer drugs are metabolised by CYPs ([@bib31]), patients on oral anticancer agents are at considerable risk for PDDIs. Moreover, a relative lack of collaboration between medical oncologists, pharmacists, and general practitioners, and the fact that computer-based medication prescription systems in hospitals and community pharmacies are usually not connected leads to PDDIs frequently going unnoticed ([@bib3]).

At present, epidemiological data regarding harmful PDDIs during oral anticancer therapy are scarce in the literature. Therefore, the aim of this study was to investigate the prevalence of PDDIs among ambulatory cancer patients on oral anticancer treatment, with the primary intent to create awareness among oncologists and pharmacists regarding the risk of potentially harmful drug--drug interactions. The secondary objective was to obtain more insight into possible determinants for the occurrence of these PDDIs.

Materials and methods
=====================

Study design and patients
-------------------------

A multicentre cross-sectional study of the prevalence of PDDIs was conducted in ambulatory cancer patients treated with oral anticancer drugs in three Dutch centres: the Maastricht University Medical Center (Maastricht), St. Radboud University Medical Centre (Nijmegen), and Deventer Teaching Hospital (Deventer). All ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who were receiving one of more oral anticancer therapies (with or without additional intravenous anticancer drugs), were included in the study. Exclusion criteria were (i) the use of (oral) experimental trial agents, (ii) age \<18 years, and (iii) the use of oral anticancer drugs for non-malignant diseases. This study was registered under number ISRCTN01739090, and was approved by the medical ethics boards of all three participating institutes.

Procedures
----------

A retrospective search was conducted in the computer-based medication prescription system of the hospital pharmacy in these three centres for the dispensing of oral anticancer drugs to outpatients over a period of 12 months (between 1 October 2010 and 1 October 2011). Medications were classified into three groups; 'anticancer drugs\', 'supportive care drugs\', and 'drugs to treat additional diseases/comorbidities\'. Anticancer drugs were defined as oncolytic drugs (Anatomical Therapeutic Chemical code (ATC-code) L01) and antihormonal agents (ATC-code L02). In addition, data on supportive care and co-medication were collected using the same computer-based medication prescription system of the hospital pharmacy. Supportive care drugs included antiemetic and analgesic drugs. Drugs for chronic and incidental use (e.g., dexamethasone during chemotherapy) were included in this study as long as they were used concurrently as was defined by [@bib39]. Information concerning type of cancer and comorbidities was collected by medical chart review. In this study, comorbidities were defined as all other diseases an individual patient might have, other than the primary disease of interest (cancer).

Renal function \[creatinine\] and liver function parameters (aspartate aminotransferase (AST), alanine aminotransferase (ALT), and *γ*-glutamyltransferase (*γ*-GT)) were extracted from the laboratory database of the hospital while an individual patient was receiving an oral anticancer agent. Laboratory abnormalities were defined as an increase of \>50% above the upper limit of normal (upper normal limits in all three medical centres: ASAT⩽35 U/L, ALAT⩽40 U/L, *γ*-GT⩽44 U/L, creatinine⩽99 *μ*mol/L).

Potential drug--drug interactions between drugs and over-the-counter (OTC) medication were not studied. When a drug formulation contained two or more pharmacologically active ingredients each drug was counted individually in the analysis (e.g., tramadol/acetaminophen). However, when a patient was taking the same medication in more than one formulation (e.g., long- and short-acting morphine) the drug was counted only once.

In this study, we have identified drug--drug combinations, within the same patient, for drugs that are known for having interacting effects, rather than the occurrence of an actual adverse event in an individual patient. Potential drug--drug interactions were identified by using the [@bib1] software (Facts and Comparisons, version 4.0, 2006), which is a commonly used and reputable source. It has been shown to have an accuracy of over 95% in detecting interactions ([@bib4]). [@bib1] software classifies interactions by the level of severity and the level of scientific evidence. A detailed classification of level of severity and scientific evidence is shown in [Figure 1](#fig1){ref-type="fig"}.

The medication regimen of each patient was also screened for: Drug combinations with potential QT-interval prolongation and/or *torsades de pointes* inducing properties using the Arizona CERT system list 1 (risk of torsades) and list 2 (possible risk of torsades) ([@bib2]). Because of the potentially severe consequences, all drug combinations with risk for QT prolongation were classified as major (QT interaction). The QT-interval prolonging potential of drugs is generally well documented and QT interactions were classified as 'probable\' as was defined in [Figure 1](#fig1){ref-type="fig"}.Drugs associated with an increased risk of falling (central nervous system (CNS)-depressant agents). First, the medication regimen of each patient was manually screened for CNS-depressant agents by using handbooks and peer-reviewed reports on scientific evidence ([@bib23]; [@bib24]; [@bib38]; [@bib15]; [@bib13]; [@bib42]). A combination of two CNS-depressant agents was counted as one interaction and defined as CNS interaction in the analysis. All CNS interactions were classified as moderate. The CNS-depressant potential of drugs is described in the literature, and CNS interactions were classified as 'probable\' as was defined in [Figure 1](#fig1){ref-type="fig"}.Drug combinations between non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, anticoagulants, aspirin, bisphosphonates, or selective serotonin reuptake inhibitors (SSRIs). These combinations were defined as a gastrointestinal (GI) interaction and were identified by using the [@bib1] software and peer-reviewed reports on scientific evidence ([@bib28]; [@bib22]; [@bib35]). The GI interactions may increase the risk of GI bleeding. Due to the potentially severe consequences all GI interactions were classified as major. The GI interactions are generally well documented, and were classified as 'probable\' as was defined in [Figure 1](#fig1){ref-type="fig"}.

A PDDI was only counted in the analysis when an 'anticancer agent\' or a 'supportive care drug\' was involved; thus, PDDIs resulting from the treatment of comorbidities were disregarded. Interactions of minor severity, being clinically not relevant, were not included in the analysis.

Statistical analysis
--------------------

To compute patient demographics, cancer type, comorbidities, number of drugs used per patient, laboratory abnormalities, and drug interaction characteristics (severity, scientific evidence, and mechanism), descriptive statistics were used. Subsequently, univariate and multivariate binary logistic regression analyses were performed to identify the potential risk factors for the occurrence of PDDIs. The occurrence of at least one DDI per patient was called the dependent variable. Predictor variables tested included age, number of drugs, presence of comorbidities (yes/no), cancer type, treatment type, solid tumour or haemato-oncology disease and laboratory abnormalities. Gender was not included as a predictor variable as certain cancer types only occur in men or women. The largest group per predictor variable was taken as the reference (Ref.) for binary or nominal variables. In the multivariate analysis predictor, variables with univariate *P*-values \<0.1 were included. Predictor variables in the multivariate analysis with a *P*-value of \<0.05 were considered statistically significant. The data were adjusted for confounders and effect modifiers. Data were collected and analysed in SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patient
-------

A total of 898 patients were included in this study, with a median age of 61 years (range 18--95 years), of which 58% were female. The median number of drugs used per person was five (range 1--24 drugs). Demographic characteristics are listed in [Table 1](#tbl1){ref-type="table"}. In 898 patients, a total of 31 different oral anticancer drugs were identified as stated in [Table 2](#tbl2){ref-type="table"}.

Drug interactions
-----------------

In total, 1359 PDDIs were identified in 426 patients (46%, 95% CI=42--50% [Figure 2](#fig2){ref-type="fig"}). In 143 patients (16%) at least one major PDDI was identified. Of all PDDIs, 15% and 83% were classified as major and moderate PDDIs, respectively. In 14% of all PDDIs, anticancer drugs were involved. A pharmacodynamic PDDI was found in 86% of all cases. The majority of cases concerned CNS interactions (*n*=848), GI interactions (*n*=97), and QT interaction (*n*=45). Most PDDIs (86%) were supported by level 2 (probable) or level 3 (suspected) scientific evidence. A stratification of the identified PDDIs by 'level of severity\', 'level of scientific evidence\', and 'mechanism of drug interaction\' is listed in [Figure 2](#fig2){ref-type="fig"}.

Potential drug--drug interactions involving anticancer drugs and supportive care agents are listed in [Table 3](#tbl3){ref-type="table"}. As the variety of drug classes is diverse, only PDDIs with potentially major consequences are reported. The drug classes most commonly involved in major PDDIs were coumarins and opioids. The QT interactions and GI interactions were also observed frequently.

Risk factors
------------

All patients were included in the binary logistic regression analysis. In the univariate analysis, the number of drugs, treatment type, cancer type, and the presence of comorbidities were associated with higher risk for PDDIs. No statistically significant association was found for age (*P*=0.124), tumour type (solid/non-solid malignancy; *P*=0.327), or laboratory abnormalities (*P*=0.295). Results of the univariate and multivariate binary logistic regression analyses are listed in [Table 4](#tbl4){ref-type="table"}. After adjustment for confounders, the number of drugs (odds ratio (OR) 1.66 (1.54--1.78); *P*\<0.0001) and cancer type (genito-urinary cancer, OR 0.25 (0.12--0.52); *P*\<0.0001) remained statistically significant.

Discussion
==========

To our knowledge, this is the first study to investigate the prevalence of PDDIs among cancer patients that are on oral anticancer treatment. In this analysis, we detected a high prevalence of PDDIs with 46% of all patients being exposed to at least one PDDI. More importantly, these PDDIs were not just theoretical in nature, 16% of all patients had at least one major PDDI that may have had harmful side effects and which usually would have needed intervention or intensive monitoring.

Most PDDIs (86%) were supported by level 2 or level 3 scientific evidence. In the majority of PDDIs, a supportive care agent was involved (86%). Potential drug--drug interactions with coumarins, whose anticoagulant effects may be altered, and fentanyl, through which plasma concentrations and toxicity of fentanyl may be increased, were most frequently registered. This also counted for drug combinations that may have led to QT-interval prolongation, or to GI toxicities. The highest prevalence concerned CNS interactions that accounted for up to 73% of all PDDIs.

The drug--drug combinations of coumarins with certain oral anticancer agents (e.g., capecitabine) may result in altered anticoagulant effects and haemorrhage due to the increased hypoprothrombinemic effects of coumarins ([@bib30]; [@bib26]; [@bib33]). In case of a PDDI, anticoagulant effects should be closely monitored and the dose of coumarins must be adjusted accordingly. Combinations of strong CYP3A4 iso-enzyme inhibitors/inducers and anticancer drugs can be potentially harmful ([@bib17]; [@bib25]). In this study, the combination of fentanyl and strong CYP3A4 iso-enzyme inhibitors (e.g., itraconazole) was frequently found. This CYP3A4 inhibitor may decrease the metabolic elimination of this opioid, resulting in increased plasma concentrations and pharmacologic effect of fentanyl. Closely monitoring for signs of excessive narcotic effects of fentanyl is indicated and dosage reduction may be required ([@bib14]; Official package labelling Actiq (fentanyl citrate), 2007).

Drug combinations that could lead to QT-interval prolongation, or to GI toxicity, can have serious or even fatal consequences, like *torsade de pointes* and NSAIDs induced ulcers, respectively ([@bib2]; [@bib28]; [@bib22]). Due to the extensive use of QT-prolonging drugs (e.g., ondansetron) and drugs that can cause GI toxicity (e.g., NSAIDs) in (haemato)-oncology these PDDIs may cause significant health risks. Concerning QT interactions, there is very little information to guide clinicians about the risks of concomitantly using QT-prolonging drugs, and how these PDDIs should be managed. Moreover, the evidence for risk of *Torsades de point* is often imperfect. Nevertheless, QT interactions are presumed to have the potential for life-threatening consequences. Drug--drug combinations that could lead to QT-interval prolongation or to GI toxicity should, if possible, be avoided.

The high prevalence of CNS interactions is of particular concern, since injuries resulting from balance disorders may have a major impact on public health. The authors acknowledge that a large number of cancer patients need CNS depressant medication (e.g., opioids, antidepressants, and benzodiazepines). However, due to the increased risk of osteoporosis and the extensive use of CNS-depressant drugs, cancer patients are particularly at risk for fractures ([@bib13]). Prescribed CNS-depressant drugs can result in an up to 47% increased risk of falls ([@bib21]). Prescription of combinations of CNS-depressant drugs may even further increase this risk ([@bib15]). Although combinations of CNS-depressant drugs are often used for therapeutic reasons, oncologists and other health-care professionals should minimise the number of CNS depressant drugs prescribed, or at least carefully assess combinations of CNS-depressant drugs and monitor for signs of balance disorders.

In this study, the number of drugs used concomitantly has been identified as a risk factor for the occurrence of PDDIs. Genito-urinary cancer showed a lower risk. It is not surprising that an increasing number of drugs used is associated with an increased risk of PDDIs and is in agreement with other studies ([@bib29]; [@bib40]). Patients with genito-urinary cancers were less likely to be exposed to PDDIs. A plausible explanation for this lower risk could be the relatively mild interaction profile of bicalutamide, which was predominately used for the oral treatment of prostate cancer in our studied population. However, many medical centres still use flutamide and nilutamide for the treatment of prostate cancer, which do have interacting potentials. This questions the generalisability of prostate cancer as a risk factor.

A great strength of this study was that the medication data in the computer-based medication prescription system were based on 'actual concurrent use\' ([@bib39]). If an oral anticancer drug was dispensed in the hospital pharmacy, then the actual use of other drugs (e.g., supportive care drugs\' and 'drugs to treat additional diseases/comorbidities\'), both on a continuous base and an incidental use, was always discussed with the patient and registered in the computer-based medication prescription system. Other strengths of our study included the large multicentre sample size, cross-sectional design, use of a large variety of oral anticancer agents, objective identification of PDDIs based on highly sensitive screening software (Facts and Comparisons, version 4.0, 2006; [@bib4] and the additional screening for QT, GI, and CNS interactions. These factors increase the validity and representativeness of this study.

A major limitation of this study is that it does not investigate the clinical impact of the PDDIs. Although [@bib7] estimated that PDDIs are responsible for the death of 4% of hospitalised cancer patients, insights into the clinical consequences of PDDIs in cancer patients remains largely unknown and should be further explored in prospective studies. Also, the true relevance of some drug--drug interactions identified by Drugs Interaction Facts software or the additional manual search may sometimes be questioned (e.g., NSAIDs and bisphosphonates or NSAIDs and SSRIs). Furthermore, it is not known to what extent precautions (e.g., dosage adjustments) were taken by the health-care professionals to prevent potentially harmful PDDIs. Since these precautions are not being accounted for in this study, this may lead to an over-detection of PDDIs by electronic PDDI databases, as was concluded by [@bib10]. Another limitation of this study was that we did not study PDDIs between prescription drugs and OTC medication. In our previous study ([@bib40]), OTC drugs were involved in 11% of all PDDIs. Although drug combinations with OTC drugs were not investigated in this study (due to the retrospective search in the computer-based medication prescription system), PDDIs with OTC drugs are relevant and can be potentially harmful ([@bib25]; [@bib37]).

Our findings were largely in accordance with other studies ([@bib29]; [@bib40]). Conversely, a comparable retrospective database study, conducted in Eastern cancer patients using oral anticancer therapy, found that only 5% of all patients had at least one PDDI ([@bib18]). A possible explanation for the higher prevalence of PDDIs in our study may be the additional search for QT, GI and CNS interactions. Nevertheless, the existence of potentially harmful PDDIs should not be neglected and needs the explicit attention of pharmacists and medical doctors.

In conclusion, over the past years there has been a sharp shift and focus towards oral anticancer drugs. The present study shows that besides their possible benefits, cancer patients on oral anticancer therapy are at considerable risk for PDDIs. It remains unknown to what extent pharmacies and medical doctors were actually aware of these PDDIs and whether they took adequate measures to prevent potentially harmful drug--drug combination. Therefore, the impact of the identified PDDIs on clinical outcomes remains partly unknown and should be further investigated in detail in future prospective studies. In the Erasmus University Medical Centre, a prospective clinical trial such as this is currently ongoing, to explore important remaining questions. For instance, the effects of duration of anticancer drug treatment and the dose of the drugs that may interact will be studied in detail.

This is particularly relevant as with the increasing numbers of new oral anticancer agents that become available, the risk for PDDIs will consequently increase. Despite this fact, in current daily practice medication review is not always common practice. We realise that many combinations of interacting drugs are unavoidable and may be administered together if appropriate precautions are taken (e.g., monitoring and dosage adjustment). However, this requires a solid medication review of all drugs used at every patient visit by an oncologist or pharmacist. Therefore, in an ideal situation, all drugs prescribed by oncologists, general practitioners, and other health-care professionals should be documented electronically, including patient\'s medical status, in computer-based patient records to identify and prevent potentially harmful PDDIs.
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###### Demographic characteristics

                                                                                               ***n***      **%**
  ----------------------------------------------------------------------------------------- -------------- -------
  Study population                                                                               898         100
  Age in years[a](#t1-fn1){ref-type="fn"}                                                    61 (18--95)     ---
  **Sex**                                                                                                  
  Female                                                                                         518        57.7
  Male                                                                                           380        42.3
  **Hospital**                                                                                             
  Radboud University Medical Center                                                              463        51.6
  University Hospital Maastricht                                                                 362        40.3
  Deventer Hospital                                                                               73         8.1
  **Cancer type**                                                                                          
  Solid malignancy                                                                               766        85.3
  Haemato-oncology                                                                               132        14.7
  **Cancer type solid malignancy**                                                                         
  Breast                                                                                         273        30.4
  Gastrointestinal (GI)                                                                          257        28.6
  Genito-urinary (GU)                                                                            102        11.4
  Neurological                                                                                    79         8.8
  Lung                                                                                            28         3.1
  Gynaecologic                                                                                    13         1.4
  Other                                                                                           15         1.6
  **Cancer type haemato-oncology**                                                                         
  Leukaemia                                                                                       40         4.5
  Myeloproliferative disease                                                                      36         4.0
  Malignant lymphoma                                                                              32         3.5
  Plasma cell dyscrasia                                                                           15         1.7
  Myelodysplastic syndrome                                                                        8          0.9
  Immunocytoma                                                                                    1          0.1
  No. of drugs used per patient[a](#t1-fn1){ref-type="fn"}                                    5 (1--24)      ---
  **No. of drugs used per patient per group**[a](#t1-fn1){ref-type="fn"}                                   
  Oral anticancer agents                                                                       1 (1--3)      ---
  Supportive care drugs[b](#t1-fn2){ref-type="fn"}                                             1 (0--9)      ---
  Other                                                                                       2 (0--17)      ---
  No. of comorbidities per patient[a,](#t1-fn1){ref-type="fn"}[c](#t1-fn3){ref-type="fn"}      1 (0--8)      ---
  **Laboratory values**[a](#t1-fn1){ref-type="fn"}                                                         
  Creatinine                                                                                 72 (26--568)    ---
  Aspartate aminotransferase                                                                 27 (4--1188)    ---
  Alanine aminotransferase                                                                   23 (5--845)     ---
  Gamma-glutamyltransferase                                                                  39 (8--1712)    ---
  Total laboratory abnormalities[d](#t1-fn4){ref-type="fn"}                                      110        12.2

Median (range).

Antiemetics and pain medication.

As we retrospectively retrieved comorbidity data from the oncology patient files, the real number of comorbidities could have been higher.

Because of missing data, the denominator is *n*=690. Liver failure (94), kidney failure (14), and combination (2).

###### Oral anticancer drugs identified

  **Drug class (ATC code)**       **Drugs (*****n***)
  ------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  **Oncolytics (L01)**            
  Alkylating agents               Temozolomide (75), Chlorambucil (34), Cyclophosphamide (26), Lomustine (9), Melphalan (9), Procarbazine (9), Busulfan (1)
  Antimetabolites                 Capecitabine (258), Hydroxyurea (41), Fludarabine (9), Mercaptopurine (8), Thioguanine (3), Uracil-Tegafur (2), Methotrexate (1)
  Protein kinase inhibitors       Imatinib (30), Sunitinib (27), Erlotinib (10), Dasatinib (9), Nilotinib (8), Sorafenib (4), Everolimus (4), Thalidomide (1)
  Topoisomerase inhibitors        Etoposide(19), Topotecan (1)
  Other oncolytics                Tretinoin (3)
  **Antihormonal agents (L02)**   
  Anti-oestrogens                 Tamoxifen (171)
  Enzyme inhibitors               Anastrozole (75), Letrozole (29), Exemestane (5)
  Anti-androgens                  Bicalutamide (76), Flutamide(3)

Abbreviations: ATC code=Anatomical Therapeutic Chemical code.

###### Major drug--drug interactions found in the database search

                                                                                                                                                                                                                                           ***n***  **Description**                                                                                                                             **Severity**  **Scientific evidence**
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- ------------------------------------------------------------------------------------------------------------------------------------------ -------------- -------------------------
  **Potential drug--drug interactions involving anticancer agents**                                                                                                                                                                                                                                                                                                                                           
  Tamoxifen+Ondansetron/Granisetron/Sotalol/Erythromycin/Levofloxacin/Methadone/Risperidone/Azithromycin[a](#t3-fn2){ref-type="fn"} (Scientific Advisory Board of the Arizona Center for Education and Research on Therapeutics (CERT))      28     Drug combinations can prolong QT interval                                                                                                      Major      2
  Coumarins+Capecitabine/Tamoxifen/Etoposide ([@bib30]; [@bib33])                                                                                                                                                                            17     Hypoprothrombinemic effects of coumarins may be increased, bleeding may occur                                                                  Major      2
  Methotrexate+Sulfamethoxazole/Trimethoprim/Acetylsalicylic acid ([@bib5]; [@bib32])                                                                                                                                                        12     Increased pharmacologic effects of methotrexate with an increased risk of bone marrow and hepatic toxicity                                     Major      2
  (Es)omeprazole+Dasatinib/Nilotinib ([@bib44])                                                                                                                                                                                               4     Proton pump inhibitors may decrease the plasma concentration of tyrosine kinase receptor inhibitors                                            Major      3
  Methotrexate+Prednisolone ([@bib19]                                                                                                                                                                                                         2     Prednisolone may decrease the total clearance of methotrexate                                                                                  Major      2
  Methotrexate+Amoxicillin/Clavunate ([@bib45])                                                                                                                                                                                               1     Penicillins may decrease the total clearance of methotrexate                                                                                   Major      4
  Perphenazine+Tamoxifen ([@bib34]                                                                                                                                                                                                            1     Pharmacologic effects of tamoxifen may be decreased by Perphenazine. Co-administration may increase the risk of breast cancer recurrence       Major      4
  **Potential drug--drug interactions involving supportive care drugs**                                                                                                                                                                                                                                                                                                                                       
  NSAIDs[b](#t3-fn3){ref-type="fn"}+Corticosteroids [c](#t3-fn4){ref-type="fn"}/SSRIs[d](#t3-fn5){ref-type="fn"}/Dipyridamole/Clopidogel/Alendronate ([@bib28]; [@bib22])                                                                    98     Increased risk of GI bleeding                                                                                                                  Major      2
  SSRIs+Metoclopramide/Tramadol ([@bib9]; [@bib16])                                                                                                                                                                                          16     Serotonin syndrome is a potential risk with this combination                                                                                   Major      4
  Fentanyl+Fluconazole/Aprepitant/Ketoconazole/Diltiazem/Itraconazole ([@bib14]; [@bib27]                                                                                                                                                    12     Increased pharmacologic effects and plasma concentrations of fentanyl                                                                          Major      2
  Haloperidol+Granisetron/Metoclopramide Ofloxacin+Methadone (Scientific Advisory Board of the Arizona Center for Education and Research on Therapeutics (CERT))                                                                              5     Drug combinations can prolong QT interval                                                                                                      Major      2
  Fluconazole+Methadone ([@bib36])                                                                                                                                                                                                            1     Increased plasma concentration and pharmacologic effects of methadone                                                                          Major      4

Abbreviations: GI=gastrointestinal; NSAIDs=non-steroidal anti-inflammatory drugs; PDDI=potential drug--drug interaction; SSRIs=selective serotonin reuptake inhibitors.

References in this table are only mentioned to clarify for the identification of a PDDI. For a comprehensive overview of all references, go to Facts&Comparisons (Facts and Comparisons, version 4.0, 2006).

NSAIDs: Acetylsalicylic acid, Diclofenac, Ibuprofen, Meloxicam, and Naproxen.

Corticosteroids: Budesonide, Dexamethasone, and Prednisolone.

SSRIs: (Es)citalopram, Fluoxetine, Paroxetine, and Venlafaxine.

###### Univariate and multivariate binary logistic regression analysis

  **Variable**                    **Unadjusted OR (95% CI)**   **Unadjusted** ***P*****-value**   **Adjusted OR (95% CI)**   **Adjusted** ***P*****-value**
  ------------------------------- ---------------------------- ---------------------------------- -------------------------- -------------------------------------
  Age                             1.01 (1.00--1.02)            0.124                              ---                        ---
  No. of drugs                    1.65 (1.54--1.76)            \<0.0001                           1.66 (1.54--1.78)          \<0.0001[a](#t4-fn2){ref-type="fn"}
  **Treatment type**                                                                                                         
  Oncolytics                      1.0 (Ref.)                   ---                                1.0 (Ref.)                 ---
  Antihormonal agents             0.39 (0.29--0.52)            \<0.0001                           0.61 (0.29--1.29)          0.196
  Others                          2.12 (0.79--5.66)            0.134                              1.27 (0.32--5.05)          0.735
  **Cancer type**                                                                                                            
  Breast                          1.0 (Ref.)                                                      1.0 (Ref.)                  
  Gastrointestinal                2.35 (1.66--3.34)            \<0.0001                           0.65 (0.29--1.44)          0.290
  Haemato-oncology                1.69 (1.10--2.58)            \<0.016                            0.45 (0.19--1.06)          0.067
  Genito-urinary                  0.53 (0.31--0.91)            0.021                              0.25 (0.12--0.52)          \<0.0001[a](#t4-fn2){ref-type="fn"}
  Neuro-oncological               1.32 (0.79--2.20)            0.293                              0.59 (0.24--1.49)          0.264
  Other oncology                  2.99 (1.66--5.41)            \<0.0001                           1.10 (0.45--2.68)          0.832
  **Tumour type**                                                                                                            
  Oncology                        1.0 (Ref.)                   ---                                ---                        ---
  Haemato-oncology                1.20 (0.83--1.75)            0.327                              ---                        ---
  **Presence of comorbidities**                                                                                              
  No                              1.0 (Ref.)                   ---                                1.0 (Ref.)                 ---
  Yes                             2.06 (1.58--2.70)            \<0.0001                           1.02 (0.70--1.48)          0.923
  **Laboratory abnormality**                                                                                                 
  No                              1.0 (Ref.)                   ---                                ---                        ---
  Yes                             1.24 (0.83--1.87)            0.295                              ---                        ---

Abbreviations: CI=confidence interval; OR=odds ratio; Ref.=Referent.

Statistically significant.
